Oncology Drug Combos Are Held Back By IP Issues, Not FDA, Pazdur Tells ASCO
This article was originally published in The Pink Sheet Daily
Executive Summary
Development of oncology drug combination products is more often held back by intellectual property issues than by FDA regulatory requirements, Oncologic Drug Products Division Director Richard Pazdur said during the American Society of Clinical Oncology meeting in New Orleans June 5
You may also be interested in...
Merck KGaA Acquires Rights For Colorectal Cancer Therapy UFT From Taiho
Germany-based Merck says it has not decided whether it will seek FDA approval for the uracil/tegafur combination; FDA deemed UFT “not approvable” for advanced colorectal cancer in 2001, when Bristol held rights to the agent.
Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.